Key Takeaways
Pharvaris N.V. (Nasdaq: PHVS) priced an underwritten offering of 3,874,664 ordinary shares at $29.68 apiece, seeking to raise gross proceeds of approximately $115 million to advance its clinical programs.
"The offering is expected to close on or about May 11, 2026, subject to satisfaction of customary closing conditions," the company said in a press release.
The offering, managed by joint book-runners including Morgan Stanley and Wells Fargo Securities, also grants underwriters a 30-day option to purchase up to an additional 581,199 shares. The new shares dilute the ownership stake of existing shareholders, a factor that typically puts short-term pressure on a company's stock price.
For investors with a long-term conviction in the company, a price drop from dilution can present an opportunity to "average down"—buying more shares at a lower price to reduce the average cost per share. This strategy, however, depends on the company's future success.
The capital raise is earmarked to fund the development of deucrictibant, Pharvaris's novel oral treatment for hereditary angioedema (HAE), a rare genetic disorder causing severe swelling attacks. The funds will support a global Phase 3 study with topline data anticipated in the third quarter of 2026 and a planned New Drug Application with the FDA in the first half of 2026.
The financing provides a critical cash infusion for Pharvaris to reach its next major clinical and regulatory milestones. Investors will be closely watching for the pivotal trial data, which will be a key determinant of the drug's commercial prospects and the company's long-term value.
This article is for informational purposes only and does not constitute investment advice.
